IMMUNOCAN
Toward enhancing activities of European institutions in the FDUSCC-IM cancer research joint institute in China
| Coordinatore | TRANSGENE SA
Organization address
address: BOULEVARD GONTHIER D ANDERNACH - PARC D'INNOVATION contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 2˙072˙438 € |
| EC contributo | 1˙992˙214 € |
| Programma | FP7-INCO
Specific Programme "Capacities": International co-operation |
| Code Call | FP7-INCO-2011-7 |
| Funding Scheme | CSA-SA |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TRANSGENE SA
Organization address
address: BOULEVARD GONTHIER D ANDERNACH - PARC D'INNOVATION contact info |
FR (ILLKIRCH-GRAFFENSTADEN) | coordinator | 570˙009.00 |
| 2 |
FUDAN UNIVERSITY SHANGHAI CANCER CENTER
Organization address
address: DONGAN ROAD 270 - XUHUI DISTRICT contact info |
CN (SHANGHAI) | participant | 761˙908.00 |
| 3 | KOBENHAVNS UNIVERSITET | DK | participant | 255˙409.00 |
| 4 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 239˙359.00 |
| 5 |
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Organization address
address: Via Venezian 1 contact info |
IT (Milan) | participant | 165˙529.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The joint institute Fudan University Shanghai Cancer Centre – Institut Mérieux laboratory (FDUSCC-IM), created in May 2010, is conducting ambitious scientific research projects on oncology in China. Its 2 founding partners, Fudan University (China) and Transgene (part of Institut Mérieux, France) wish to increase their translational medical research cooperation with European countries. In a first step, collaboration will enlarge to an active partnership with Danish, Italian and German teams, with the following objectives: (i) increase the EU-China knowledge exchanges in the field of cancer prognosis – by organizing in China summer schools, seminars and international conferences, as well as by hosting PhDs and post PhD research fellows in the joint institute, (ii) enhance the research capacity and the technological transfer to the joint institute – by providing adequate human resources and equipment to conduct beyond the state-of-the-art oncology research, (iii) promote a reference Euro-Asian centre on Chinese cancer prognosis – by spreading the knowledge and by raising awareness in China and European Union. Research activities will be held in China in collaboration with the new European partners, in order to enhance current research activities of the joint institute and to create durable links between Chinese and European teams. Current research is focused on immune phenotype as personalized medical biomarker for prognosis of Chinese cancer patients, and will be extended to new types of cancer and biomarkers. These prognosis studies will help to guide clinical decision-making by facilitating the selection of appropriate treatment options. Ultimately, this FP7 INCOLAB is an opportunity to build a Euro-Asian reference centre for medical and scientific research on cancer and to extend the already existing cooperation between the FDUSCC-IM laboratory and Europe by considering the opening of the joint institute to additional European member.'